Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609582 · ClinicalTrials.gov registry record · Phase 3
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,207
- Enrollment target
NCT01609582 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 3,207 participants.
The verdict
NCT01609582, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,207 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
Interventions
- DRUG TAK-875
- DRUG TAK-875 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,207 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609582
The ClinicalTrials.gov registry entry for NCT01609582 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3,207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-875 is the first listed.
NCT01609582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01609582 about?
NCT01609582 is a clinical study titled "Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease". The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
What is the current status of trial NCT01609582?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,207 participants. The study started on 2012-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01609582?
The interventions under investigation include: TAK-875 (DRUG), TAK-875 Placebo (DRUG).
Who is sponsoring clinical trial NCT01609582?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.